Arcellx, Inc. advances anito-cel CAR-T therapy for relapsed/refractory multiple myeloma. Click for ACLX pivotal trials, FDA ...

FDA reviewers said in briefing documents that the benefit-risk profile of the drug for the treatment of multiple myeloma “remains unclear.” ...

"If patients have one feature, that is bad, and if they have two or more, that is really bad," he said. "Regardless of ...

MiROM identifies proteins by using mid-infrared light to detect molecular vibrations – essentially the natural "dance" of molecules within protein structures. Unlike optical spectroscopy, which ...

Multiple myeloma involves a comprehensive approach that combines blood tests, imaging, and bone marrow studies. Learn about ...

Medically reviewed by Archana Sharma, DO There are several treatment options for multiple myeloma. Since this disease varies ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more ...

With ever-growing treatment options, clinical care access and a new focus on integrative strategies, cancer centers are constantly upgrading their services and options for patients. Becker’s asked ...

Researchers from Helmholtz Munich and the Technical University of Munich have developed a novel method to track cancer ...

Panelists discuss how preparing multiple myeloma patients for treatment involves structured education, emotional support, and proactive symptom management—emphasizing clear communication about the ...

Panelists discuss how treatment decisions in multiple myeloma are guided by disease risk, patient health, and evolving ...

If you’re going to be cut short, you sure as hell better get out and enjoy it." So he races with the World of Outlaws.